$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420415010251 Filed on February 17, 2015

Income Statement

Concept	2014 Q4	2014 Q1	2013 Q4
Revenue	$1.363M	$1.028M	$1.693M
YoY Change	-19.49%		153.56%
Cost Of Revenue	$700.0K	$1.046M	$995.0K
YoY Change	-29.65%		272.95%
Gross Profit	$663.0K	-$18.00K	$699.0K
YoY Change	-5.15%		74.36%
Gross Profit Margin	48.64%	-1.75%	41.29%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$2.293M		$1.291M
YoY Change	77.63%		441.77%
% of Gross Profit	345.85%		184.67%
Depreciation & Amortization	$210.0K	$120.0K	$110.0K
YoY Change	90.91%	33.33%	22.22%
% of Gross Profit	31.67%		15.74%
Operating Expenses	$3.221M	$2.365M	$1.936M
YoY Change	66.37%		186.77%
Operating Profit	-$2.557M	-$2.384M	-$1.237M
YoY Change	106.71%		351.11%
Interest Expense	$66.15K		$359.1K
YoY Change	-81.58%		461.81%
% of Operating Profit
Other Income/Expense, Net	$9.974M	-$31.65M	$175.0K
YoY Change	5599.43%		-98.18%
Pretax Income	$21.02M		-$1.062M
YoY Change	-2079.26%		-111.34%
Income Tax	$0.00	-$295.0K	$0.00
% Of Pretax Income	0.0%
Net Earnings	$7.417M	-$86.80M	-$1.062M
YoY Change	-798.4%		-111.34%
Net Earnings / Revenue	544.17%	-8443.39%	-62.73%
Basic Earnings Per Share	$0.03	-$0.16	$0.00
Diluted Earnings Per Share	-$0.01	-$0.16	$0.00
COMMON SHARES
Basic Shares Outstanding	601.1M shares	618.4M shares	508.6M shares
Diluted Shares Outstanding	770.6M shares		508.6M shares

Balance Sheet

Concept	2014 Q4	2014 Q1	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.270M	$6.940M	$1.080M
YoY Change	665.74%	1775.68%	1442.86%
Cash & Equivalents	$8.274M	$6.942M	$1.081M
Short-Term Investments
Other Short-Term Assets	$330.0K	$320.0K	$280.0K
YoY Change	17.86%	113.33%	300.0%
Inventory	$2.860M	$1.932M	$1.532M
Prepaid Expenses
Receivables	$1.710M	$732.1K	$1.024M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.19M	$9.925M	$3.918M
YoY Change	236.67%	290.22%	138.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.480M	$4.200M	$4.117M
YoY Change	33.12%	4.24%	0.16%
Goodwill
YoY Change
Intangibles		$6.350M	$6.315M
YoY Change		814.42%
Long-Term Investments	$60.00K	$3.350M	$3.360M
YoY Change	-98.21%	0.3%	0.6%
Other Assets	$668.0K	$3.843M	$560.0K
YoY Change	19.29%	653.61%	-5.08%
Total Long-Term Assets	$12.51M	$14.39M	$14.36M
YoY Change	-12.88%	67.72%	64.48%
TOTAL ASSETS
Total Short-Term Assets	$13.19M	$9.925M	$3.918M
Total Long-Term Assets	$12.51M	$14.39M	$14.36M
Total Assets	$25.70M	$24.32M	$18.28M
YoY Change	40.62%	118.58%	76.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.210M	$2.210M	$1.990M
YoY Change	61.31%	66.17%	42.14%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$670.0K	$530.0K	$6.390M
YoY Change	-89.51%	-11.67%
Long-Term Debt Due	$460.0K	$87.57K	$3.390M
YoY Change	-86.43%	-97.42%	-12.85%
Total Short-Term Liabilities	$4.350M	$6.161M	$12.51M
YoY Change	-65.21%	15.0%	132.44%
LONG-TERM LIABILITIES
Long-Term Debt	$2.070M	$18.87K	$0.00
YoY Change
Other Long-Term Liabilities	$464.4K	$131.1K	$98.34K
YoY Change	372.27%	43.22%	-99.43%
Total Long-Term Liabilities	$51.89M	$99.36M	$10.70M
YoY Change	384.96%	587.99%	-38.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.350M	$6.161M	$12.51M
Total Long-Term Liabilities	$51.89M	$99.36M	$10.70M
Total Liabilities	$56.24M	$105.5M	$23.20M
YoY Change	142.37%	432.95%	2.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$187.0M	-$225.0M	-$138.2M
YoY Change	35.31%	75.2%
Common Stock	$156.8M	$144.1M	$133.6M
YoY Change	17.36%	20.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K	$306.8K
YoY Change	0.0%	0.0%
Treasury Stock Shares	100.0K shares	100.0K shares	100.0K shares
Shareholders Equity	-$30.54M	-$81.20M	-$4.927M
YoY Change
Total Liabilities & Shareholders Equity	$25.70M	$24.32M	$18.28M
YoY Change	40.62%	118.58%	76.25%

Cashflow Statement

Concept	2014 Q4	2014 Q1	2013 Q4
OPERATING ACTIVITIES
Net Income	$7.417M	-$86.80M	-$1.062M
YoY Change	-798.4%		-111.34%
Depreciation, Depletion And Amortization	$210.0K	$120.0K	$110.0K
YoY Change	90.91%	33.33%	22.22%
Cash From Operating Activities	-$2.610M	-$1.480M	-$1.460M
YoY Change	78.77%	572.73%	342.42%
INVESTING ACTIVITIES
Capital Expenditures	-$390.0K	-$130.0K	-$290.0K
YoY Change	34.48%	550.0%	866.67%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$60.00K	-$30.00K
YoY Change	-100.0%	-25.0%	-66.67%
Cash From Investing Activities	-$380.0K	-$70.00K	-$310.0K
YoY Change	22.58%	-216.67%	158.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.640M	7.400M	2.090M
YoY Change	74.16%	1441.67%	596.67%
NET CHANGE
Cash From Operating Activities	-2.610M	-1.480M	-1.460M
Cash From Investing Activities	-380.0K	-70.00K	-310.0K
Cash From Financing Activities	3.640M	7.400M	2.090M
Net Change In Cash	650.0K	5.850M	320.0K
YoY Change	103.13%	1728.12%	-313.33%
FREE CASH FLOW
Cash From Operating Activities	-$2.610M	-$1.480M	-$1.460M
Capital Expenditures	-$390.0K	-$130.0K	-$290.0K
Free Cash Flow	-$2.220M	-$1.350M	-$1.170M
YoY Change	89.74%	575.0%	290.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	464428	USD
CY2014Q1	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	38103446	USD
CY2014Q1	eltp	Derivative Liability Preferred Shares DerivativeLiabilityPreferredShares	60981570	USD
CY2014Q4	eltp	Derivative Liability Preferred Shares DerivativeLiabilityPreferredShares	32285714	USD
CY2014Q4	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	16941588	USD
CY2014Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	99355050	USD
CY2014Q1	us-gaap	Liabilities Liabilities	105515874	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	560244	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	143555091	USD
CY2014Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-225006646	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-81198152	USD
CY2014Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	665881	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	668022	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3212056	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	51885620	USD
CY2014Q4	us-gaap	Liabilities Liabilities	56240527	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	608967	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	156170459	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-187011861	USD
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-30539276	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25701251	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24317722	USD
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	134083	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	100481	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5508377	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6144310	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2014Q1	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	121698	USD
CY2014Q4	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	132330	USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	690000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	560242430	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	608963698	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	560142430	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	608863698	shares
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	961401	USD
CY2013Q4	us-gaap	License And Services Revenue LicenseAndServicesRevenue	743125	USD
	us-gaap	Contracts Revenue ContractsRevenue	69255	USD
CY2014Q4	us-gaap	Contracts Revenue ContractsRevenue	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	3573832	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	3781000	USD
CY2013Q4	us-gaap	Sales Revenue Net SalesRevenueNet	1693246	USD
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	1362901	USD
	us-gaap	Cost Of Revenue CostOfRevenue	2190229	USD
	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	2814599	USD
CY2013Q4	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	891838	USD
CY2014Q4	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	1014628	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1147958	USD
CY2014Q4	us-gaap	License And Services Revenue LicenseAndServicesRevenue	348273	USD
	us-gaap	Contracts Revenue ContractsRevenue	5000	USD
CY2013Q4	us-gaap	Contracts Revenue ContractsRevenue	58283	USD
CY2014Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1523341	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2700853	USD
CY2014Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	409145	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	22053	USD
CY2014Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	140707	USD
	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	2356619	USD
	us-gaap	Cost Of Revenue CostOfRevenue	2109853	USD
CY2013Q4	us-gaap	Cost Of Revenue CostOfRevenue	994582	USD
CY2014Q4	us-gaap	Cost Of Revenue CostOfRevenue	699654	USD
	us-gaap	Gross Profit GrossProfit	1383603	USD
	us-gaap	Gross Profit GrossProfit	1671147	USD
CY2013Q4	us-gaap	Gross Profit GrossProfit	698664	USD
CY2014Q4	us-gaap	Gross Profit GrossProfit	663247	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2715126	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9878465	USD
CY2013Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1290858	USD
CY2014Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2292957	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1143487	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1992293	USD
CY2013Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	494469	USD
CY2014Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	625129	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52085	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	166647	USD
CY2013Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23662	USD
CY2014Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	89505	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	372227	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	683663	USD
CY2013Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	126827	USD
CY2014Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	212967	USD
	us-gaap	Operating Expenses OperatingExpenses	4282925	USD
	us-gaap	Operating Expenses OperatingExpenses	12721068	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	1935816	USD
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	3220558	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2899322	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11049921	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1237152	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2557311	USD
	us-gaap	Interest Expense InterestExpense	689852	USD
	us-gaap	Interest Expense InterestExpense	214434	USD
CY2013Q4	us-gaap	Interest Expense InterestExpense	359130	USD
CY2014Q4	us-gaap	Interest Expense InterestExpense	66153	USD
	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	-2576278	USD
	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	21161859	USD
CY2013Q4	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	656844	USD
CY2014Q4	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	10040234	USD
	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	-3462104	USD
	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	26423356	USD
CY2013Q4	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	4228	USD
CY2014Q4	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	13600000	USD
	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	40428	USD
	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	0	USD
CY2013Q4	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	-632	USD
CY2014Q4	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	0	USD
	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	1670678	USD
CY2013Q4	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
CY2014Q4	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
	us-gaap	Other Income OtherIncome	19831	USD
	us-gaap	Other Income OtherIncome	0	USD
CY2013Q4	us-gaap	Other Income OtherIncome	0	USD
CY2014Q4	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6876104	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	49041459	USD
CY2013Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	175301	USD
CY2014Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	23574081	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9775426	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	37991538	USD
CY2013Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1061851	USD
CY2014Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	21016770	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2269	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3248	USD
CY2013Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9777695	USD
	us-gaap	Net Income Loss NetIncomeLoss	37994786	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-1061851	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	21016770	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	eltp	Stockissuedduringperiodvaluepaymentofemployeesalaries Stockissuedduringperiodvaluepaymentofemployeesalaries	17895	USD
	eltp	Conversionofseriesbseriescandseriesepreferredsharesintocommonsharesvalue Conversionofseriesbseriescandseriesepreferredsharesintocommonsharesvalue	2272500	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9777695	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	37994786	USD
CY2013Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1061851	USD
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	439720987	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	581375865	shares
CY2013Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	508638816	shares
CY2014Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	601109708	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	439720987	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	750872145	shares
CY2013Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	508638816	shares
CY2014Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	770605988	shares
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	71913	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	203850	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	155169	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	430932	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	53368	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	108216	USD
CY2013Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	17789	USD
CY2014Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	45214	USD
CY2013Q4	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-2896	USD
CY2014Q4	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	24010	USD
CY2014Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	18824	USD
CY2014Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	16437	USD
CY2014Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	7573	USD
CY2014Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	48019	USD
	us-gaap	Description Of Lessee Leasing Arrangements Operating Leases DescriptionOfLesseeLeasingArrangementsOperatingLeases	initial term that expires on December 31, 2016, and the Company has the option to renew the lease for two additional terms of five years each
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3069666	shares
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4813334	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9678329	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	166644	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	16364	USD
	eltp	Stock Issued During Period Value Issued For Capital Purchase Agreement StockIssuedDuringPeriodValueIssuedForCapitalPurchaseAgreement	0	USD
	eltp	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	535086	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10000	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	21016770	USD
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	0	USD
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	-47585215	USD
CY2013Q4	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	0	USD
CY2014Q4	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	-23640234	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	0	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9590429	USD
CY2013Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	0	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2623464	USD
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	169496280	shares
CY2013Q4	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2014Q4	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	169496280	shares
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	334277	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	648505	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	67449	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	344500	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	679771	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	17895	USD
	eltp	Interest Expense Non Cash InterestExpenseNonCash	469805	USD
	eltp	Interest Expense Non Cash InterestExpenseNonCash	0	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	52085	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	166644	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	5698	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	29200	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	1070	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	1136	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	359130	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	982303	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	173499	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	931126	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	150783	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-48656	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	315980	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	346007	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-10000	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-10000	USD
	eltp	Increase Decrease In Derivative Interest Payable Net IncreaseDecreaseInDerivativeInterestPayableNet	-27020	USD
	eltp	Increase Decrease In Derivative Interest Payable Net IncreaseDecreaseInDerivativeInterestPayableNet	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2741608	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11246722	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	411297	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	1385227	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	22878	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	12815	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	59194	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	123912	USD
	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	0	USD
	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	5000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-493369	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3478046	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3510000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9678329	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	164583	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	545086	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	320150	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	137131	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1110000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3946746	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9100828	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	711769	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1332152	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	369023	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1080792	USD
	us-gaap	Interest Paid InterestPaid	160680	USD
	us-gaap	Interest Paid InterestPaid	142772	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	2269	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	642477	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	320522	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	786527	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	9777524	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	2272500	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	5597317	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
	us-gaap	Notes Issued1 NotesIssued1	5597317	USD
	us-gaap	Notes Issued1 NotesIssued1	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS INC /NV/
	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	ELTP
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	618411948	shares
	eltp	Change In Fair Value Of Convertible Note Derivative Instruments ChangeInFairValueOfConvertibleNoteDerivativeInstruments	-127273	USD
	eltp	Change In Fair Value Of Convertible Note Derivative Instruments ChangeInFairValueOfConvertibleNoteDerivativeInstruments	0	USD
CY2013Q4	eltp	Change In Fair Value Of Convertible Note Derivative Instruments ChangeInFairValueOfConvertibleNoteDerivativeInstruments	-127273	USD
CY2014Q4	eltp	Change In Fair Value Of Convertible Note Derivative Instruments ChangeInFairValueOfConvertibleNoteDerivativeInstruments	0	USD

Files In Submission

Name	View Source	Status
0001144204-15-010251-index-headers.html	Edgar Link	pending
0001144204-15-010251-index.html	Edgar Link	pending
0001144204-15-010251.txt	Edgar Link	pending
0001144204-15-010251-xbrl.zip	Edgar Link	pending
eltp-20141231.xml	Edgar Link	completed
eltp-20141231.xsd	Edgar Link	pending
eltp-20141231_cal.xml	Edgar Link	unprocessable
eltp-20141231_def.xml	Edgar Link	unprocessable
eltp-20141231_lab.xml	Edgar Link	unprocessable
eltp-20141231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlogo.jpg	Edgar Link	pending
v400439_10q.htm	Edgar Link	pending
v400439_ex10-82.htm	Edgar Link	pending
v400439_ex10-83.htm	Edgar Link	pending
v400439_ex10-84.htm	Edgar Link	pending
v400439_ex31-1.htm	Edgar Link	pending
v400439_ex31-2.htm	Edgar Link	pending
v400439_ex32-1.htm	Edgar Link	pending
v400439_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2014 Q4 Form 10-Q Financial Statement

#000114420415010251 Filed on February 17, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2014 Q4 Form 10-Q Financial Statement

#000114420415010251 Filed on February 17, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp